References
- Merril J A, Creasman W T. Lesions of the corpus uteri. Obstetrics and Gynecology5th edn., D N Danforth, J R Scott. JB Lippincott Company, Philadelphia 1986; 1068–96
- Buttram V C, Reiter R C. Uterine leiomyomata. Surgical treatment of the infertile female, V C Buttram, R C Reiter. Williams & Wilkins, Baltimore 1985; 201–28
- Mintz P D, Sullivan M F. Preoperative crossmatch ordering and blood use in elective hysterectomy. Obstet Gynecol 1985; 65: 389–92
- Shaw R W, Fraser H M. Use of superactive luteinizing hormone releasing hormone (LHRH) agonist in the treatment of menorrhagia. Br J Obstet Gynaecol 1984; 91: 913–16
- Lee G R, Wintrobe M M, Bunn H F. Iron deficiency anemia and the sideroblastic anemias. Harrison's Principles of Internal Medicine9th edn., K J Isselbacher, R D Adams, E Braunwald, R G Petersdorf, J D Wilson. McGraw-Hill Book Company, New York 1980; 1514–18
- Dicker R C, Greenspan J R, Strauss L T, et al. Complications of abdominal and vaginal hysterectomy among women of reproductive age in the United States. Am J Obstet Gynecol 1982; 144: 841–8
- Friedman A J, Barbieri R L, Doubilet P M, Fine C, Schiff I. A randomized double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertil Steril 1988; 49: 404–9
- West C P, Lumsden M A, Lawson S, Williamson J, Baird D T. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot. Fertil Steril 1987; 48: 45–51